Human Amniotic Membrane Derived-mesenchymal Stem Cells Induce C6 Glioma Apoptosis in Vivo Through the Bcl-2/caspase Pathways

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2011 May 11

PMID 21556762

Citations 27

Authors

Hongliang Jiao

Fangxia Guan

Bo Yang

Jianbin Li

Laijun Song

Xiang Hu

Ying Du

Affiliations

Soon will be listed here.

Abstract

High-grade gliomas are difficult to treat. We examined the therapeutic effect of intratumoral administration of human amniotic membrane derived-mesenchymal stem cells (hAMCs) on the growth of gliomas. Tumor volume of the control group was 1632±316 mm3 on day 30, and the group treated with a single intratumoral dose of hAMCs had a tumor volume of 1128±269 mm3 (P<0.05). Thus, administration of hAMCs significantly reduced tumor size. In rat glioma tissues treated with single and multiple dosages of hAMCs, there was a reduction in tumor volume of approximately 30.9 and 49.5%, respectively. We further evaluated the glioma tissue using Western blotting analysis and observed that the expression of Bax, caspase-8 and caspase-3 were greatly increased and the expression of Bcl-2 was greatly decreased in tumors treated with hAMCs. Sections of nude mice treated with hAMCs clearly showed the presence of an increase in apoptotic cells. The data collected herein confirms for the first time that hAMCs can inhibit C6 glioma growth and induce apoptosis of C6 gliomas in vivo. This demonstrates that hAMCs are a potential new therapeutic agent for the treatment of gliomas.

Citing Articles

Evaluation of the Anti-Cancer Potential of Extracellular Vesicles Derived from Human Amniotic Fluid Stem Cells: Focus on Effective miRNAs in the Treatment of Melanoma Progression.

Gatti M, Beretti F, Ravegnini G, Gorini F, Ceneri E, Bertucci E Int J Mol Sci. 2024; 25(23).

PMID: 39684214 PMC: 11641077. DOI: 10.3390/ijms252312502.

Transcriptomic analysis reveals the anti-cancer effect of gestational mesenchymal stem cell secretome.

Vaiasicca S, Melone G, James D, Quintela M, Xiao J, Yao S Stem Cells Transl Med. 2024; 13(7):693-710.

PMID: 38584493 PMC: 11227973. DOI: 10.1093/stcltm/szae024.

Application of the Human Amniotic Membrane as an Adjuvant Therapy for the Treatment of Hepatocellular Carcinoma.

Abou-Shanab A, Gaser O, Salah R, El-Badri N Adv Exp Med Biol. 2023; 1470:129-146.

PMID: 38036871 DOI: 10.1007/5584_2023_792.

Comparison of the effects of preservation methods on structural, biological, and mechanical properties of the human amniotic membrane for medical applications.

Jafari A, Mirzaei Y, Hussein Mer A, Rezaei-Tavirani M, Jafari Z, Niknejad H Cell Tissue Bank. 2023; 25(1):305-323.

PMID: 37840108 DOI: 10.1007/s10561-023-10114-z.

Apoptotic effects of human amniotic fluid mesenchymal stem cells conditioned medium on human MCF-7 breast cancer cell line.

Pashaei-Asl R, Pashaiasl M, Ebrahimie E, Lale Ataei M, Paknejad M Bioimpacts. 2023; 13(3):191-206.

PMID: 37431479 PMC: 10329748. DOI: 10.34172/bi.2022.23813.

References

Kim S, Lim J, Park S, Jeong C, Oh J, Jeong M . Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res. 2008; 68(23):9614-23. DOI: 10.1158/0008-5472.CAN-08-0451. View

Laflamme M, Murry C . Regenerating the heart. Nat Biotechnol. 2005; 23(7):845-56. DOI: 10.1038/nbt1117. View

Khakoo A, Pati S, Anderson S, Reid W, Elshal M, Rovira I . Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med. 2006; 203(5):1235-47. PMC: 2121206. DOI: 10.1084/jem.20051921. View

Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M . Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori. 2007; 93(3):248-56. DOI: 10.1177/030089160709300304. View

Tomayko M, Reynolds C . Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989; 24(3):148-54. DOI: 10.1007/BF00300234. View

Hassouna I, Wickert H, Zimmermann M, Gillardon F . Increase in bax expression in substantia nigra following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment of mice. Neurosci Lett. 1996; 204(1-2):85-8. DOI: 10.1016/0304-3940(96)12323-5. View

Euhus D, Hudd C, LaRegina M, Johnson F . Tumor measurement in the nude mouse. J Surg Oncol. 1986; 31(4):229-34. DOI: 10.1002/jso.2930310402. View

Desagher S, Martinou J . Mitochondria as the central control point of apoptosis. Trends Cell Biol. 2000; 10(9):369-77. DOI: 10.1016/s0962-8924(00)01803-1. View

Scheda A, Finjap J, Tuettenberg J, Brockmann M, Hochhaus A, Hofheinz R . Efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma. Tumori. 2007; 93(1):31-6. DOI: 10.1177/030089160709300107. View

10.

Adams J, Cory S . Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci. 2001; 26(1):61-6. DOI: 10.1016/s0968-0004(00)01740-0. View

11.

Secchiero P, Zorzet S, Tripodo C, Corallini F, Melloni E, Caruso L . Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS One. 2010; 5(6):e11140. PMC: 2886845. DOI: 10.1371/journal.pone.0011140. View

12.

Reed J . Mechanisms of apoptosis. Am J Pathol. 2000; 157(5):1415-30. PMC: 1885741. DOI: 10.1016/S0002-9440(10)64779-7. View

13.

Zhao P, Ise H, Hongo M, Ota M, Konishi I, Nikaido T . Human amniotic mesenchymal cells have some characteristics of cardiomyocytes. Transplantation. 2005; 79(5):528-35. DOI: 10.1097/01.tp.0000149503.92433.39. View

14.

Mannello F, Tonti G, Bagnara G, Papa S . Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells. Stem Cells. 2005; 24(3):475-81. DOI: 10.1634/stemcells.2005-0333. View

15.

Yip K, Reed J . Bcl-2 family proteins and cancer. Oncogene. 2008; 27(50):6398-406. DOI: 10.1038/onc.2008.307. View

16.

Han X, Meng X, Yin Z, Rogers A, Zhong J, Rillema P . Inhibition of intracranial glioma growth by endometrial regenerative cells. Cell Cycle. 2009; 8(4):606-10. DOI: 10.4161/cc.8.4.7731. View

17.

Wei Z, Chen N, Guo H, Wang X, Xu F, Ren Q . Bone marrow mesenchymal stem cells from leukemia patients inhibit growth and apoptosis in serum-deprived K562 cells. J Exp Clin Cancer Res. 2009; 28:141. PMC: 2779804. DOI: 10.1186/1756-9966-28-141. View

18.

Kang S, Kim J, Nam D, Park K . Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Neurol Med Chir (Tokyo). 2005; 45(5):232-8. DOI: 10.2176/nmc.45.232. View

19.

Kim D, Kim J, Lee J, Choi S, Kim J, Jeun S . Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells. Stem Cells Dev. 2008; 18(3):511-9. DOI: 10.1089/scd.2008.0050. View

20.

Desjardins A, Quinn J, Vredenburgh J, Sathornsumetee S, Friedman A, Herndon J . Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007; 83(1):53-60. DOI: 10.1007/s11060-006-9302-2. View